We discussed the “I’m In” program in our latest Blog article, Lack of Diversity in Clinical Trials, and it is in the news again! Other items of interest this week: Pfizer, AstraZeneca update and a Cancer Drug on hold.
1. More states are supporting the “I’m In” program, Virginia being the most recent!
2. AstraZeneca Board rejected the Pfizer proposal, but Pfizer’s CEO believes “it is in the best interest of both companies” to make a deal.
3. Merck has ceased the study of a drug that was developed with hopes and expectations of treating ovarian cancer.